Small Opus Genetics (IRD) insider sale made to cover RSU taxes

Rhea-AI Filing Summary

Opus Genetics, Inc. executive Amy Zaremba Rabourn reported an automatic sale of 1,641 shares of common stock at a weighted average price of $5.204 per share. The company executed the sale to cover tax withholding obligations from a restricted stock unit vesting event.

This was not a discretionary trade by the officer. After the sale, she still directly holds 188,671 shares, so the transaction represents a small portion of her total reported holdings.

Insights

Insider transactions analyst

Routine, non-discretionary insider sale to cover RSU taxes.

The filing shows Amy Zaremba Rabourn, an officer of Opus Genetics, with an automatic sale of 1,641 common shares at a weighted average of $5.204 per share. Footnotes state the sale was required by the company to satisfy tax withholding from an RSU vesting.

This means the transaction is mechanistic, not a discretionary decision to reduce exposure. She continues to hold 188,671 shares directly after the sale, indicating only a small fraction of her position was affected. As a result, the informational value for investors is limited and overall impact appears neutral.

Insider Trade Summary

Net Seller: 1,641 shares ($8,540)

Net Sell 1 txn

Insider Zaremba Rabourn Amy

Role Head of Fin. Quality Assurance

Sold 1,641 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,641	$5.204	$9K

Holdings After Transaction: Common Stock — 188,671 shares (Direct, null)

Footnotes (1)

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,641 shares Weighted average sale price: $5.204 per share Shares held after transaction: 188,671 shares +1 more

4 metrics

Shares sold 1,641 shares Automatic sale on 2026-04-23 to cover tax withholding

Weighted average sale price $5.204 per share Common stock sale related to RSU vesting

Shares held after transaction 188,671 shares Direct ownership following reported sale

Sale price range $5.2038–$5.2051 per share Multiple trades within reported price band

Key Terms

restricted stock units, tax withholding obligations, weighted average price, open-market sale

4 terms

restricted stock units financial

"a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required by the Company to satisfy tax withholding obligations that arose"

weighted average price financial

"The price in column 4 represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaremba Rabourn Amy

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Fin. Quality Assurance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		1,641	D	$5.204(2)	188,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Amy Rabourn	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Opus Genetics (IRD) report for Amy Zaremba Rabourn?

Opus Genetics reported that officer Amy Zaremba Rabourn had 1,641 common shares sold at a weighted average price of $5.204 per share. According to the filing, the sale was executed automatically by the company in connection with tax obligations from a restricted stock unit vesting.

Was the Opus Genetics (IRD) insider sale a discretionary trade?

No. The filing states the 1,641-share sale “does not represent a discretionary trade” by Amy Zaremba Rabourn. The company sold the shares automatically to satisfy tax withholding obligations triggered by a restricted stock unit vesting and settlement event, making it a routine administrative transaction.

How many Opus Genetics (IRD) shares does the insider hold after the sale?

After the tax-related sale, Amy Zaremba Rabourn directly holds 188,671 shares of Opus Genetics common stock. This indicates the 1,641 shares sold represent only a small portion of her reported direct holdings, leaving her overall ownership position largely unchanged by this single transaction.

What price range were the Opus Genetics (IRD) shares sold at in this Form 4?

The filing reports a weighted average sale price of $5.204 per share. Footnotes explain the shares were sold in multiple trades at prices ranging from $5.2038 to $5.2051, and the insider can provide the exact breakdown of shares at each price upon request.

Why were Opus Genetics (IRD) shares sold in connection with restricted stock units?

The company sold 1,641 shares on behalf of Amy Zaremba Rabourn to cover tax withholding obligations from a restricted stock unit vesting and settlement. This is a common mechanism where part of an equity award is sold to pay required taxes rather than the insider paying cash.